Dcmu

Dcmu

SCHEMBL3316481

CC(C)[C@H](N)C(=O)O.CN(C)C(=O)Nc1ccc(Cl)c(Cl)c1

nearest known ligand 0.71

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APEX1 P27695 1/20 0.71
GAA P10253 2/20 0.49
ALDH1A1 P00352 2/20 0.49
KDM4E B2RXH2 1/20 0.49
GLA P06280 1/20 0.49
HPGD P15428 1/20 0.49
TSHR P16473 2/20 0.48
EPHX1 P07099 1/20 0.46
EPHX2 P34913 1/20 0.46
CYP3A4 P08684 1/20 0.44
SLC1A3 P43003 1/20 0.44
SLC1A2 P43004 1/20 0.44
SLC1A1 P43005 1/20 0.44
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CA2 P00918 1/20 0.43
CA4 P22748 1/20 0.43
CA5A P35218 1/20 0.43
CA9 Q16790 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Linuron SCHEMBL9100946 0.88 KMT2A (0.58) APEX1GAAALDH1A1KDM4EGLA
Dcmu SCHEMBL29349863 0.84 APEX1 (1.00) APEX1GAAALDH1A1KDM4EGLA
Dcmu SCHEMBL1352353 0.84 APEX1 (1.00) APEX1GAAALDH1A1KDM4EGLA
Dcmu SCHEMBL7279 0.84 APEX1 (1.00) APEX1GAAALDH1A1KDM4EGLA
Dcmu SCHEMBL5810138 0.83 APEX1 (0.90) APEX1GAAALDH1A1KDM4EGLA
Dcmu SCHEMBL28964105 0.83 APEX1 (0.96) APEX1GAAALDH1A1KDM4EGLA
Dcmu SCHEMBL20723892 0.83 APEX1 (0.96) APEX1GAAALDH1A1KDM4EGLA
Dcmu SCHEMBL20723673 0.83 APEX1 (0.96) APEX1GAAALDH1A1KDM4EGLA
Dcmu SCHEMBL10491599 0.83 APEX1 (0.96) APEX1GAAALDH1A1KDM4EGLA
Dcmu SCHEMBL28379561 0.83 APEX1 (0.96) APEX1GAAALDH1A1KDM4EGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180235992-A1 IMMUNOTHERAPIES FOR MALIGNANT, NEURODEGENERATIVE AND DEMYELINATING DISEASES BY THE USE OF TARGETED NANOCARRIERS RODOS BIOTARGET GMBH (DE) 2018-08-23 US disclosed
EP-3328367-A1 IMMUNOTHERAPIES FOR MALIGNANT, NEURODEGENERATIVE AND DEMYELINATING DISEASES BY THE USE OF TARGETED NANOCARRIERS Rodos BioTarget GmbH (DE) 2018-06-06 EP disclosed
WO-2017017148-A1 IMMUNOTHERAPIES FOR MALIGNANT, NEURODEGENERATIVE AND DEMYELINATING DISEASES BY THE USE OF TARGETED NANOCARRIERS RODOS BIOTARGET GMBH (DE) 2017-02-02 WO disclosed
US-20100105640-A1 Aromatase Inhibitors for Emergency Contraception CASPER ROBERT F 2010-04-29 US disclosed
EP-1898923-A4 AROMATASE INHIBITORS FOR EMERGENCY CONTRACEPTION CASPER ROBERT F (CA) 2009-05-20 EP disclosed
US-20080207733-A1 Composition for the Treatment of Vitiligo CENTRO DE HISTOTERAPIA PLACENTARIA (CU) 2008-08-28 US disclosed
EP-1898923-A1 AROMATASE INHIBITORS FOR EMERGENCY CONTRACEPTION Casper, Robert F. (CA) 2008-03-19 EP disclosed
EP-1661565-B1 COMPOSITION COMPRISING L-PROLINE FOR THE TREATMENT OF VITILIGO CT DE HISTOTERAPIA PLACENTARIA (CU) 2007-10-24 EP disclosed
EP-1217884-B1 METHOD FOR MATURATION OF CONIFER SOMATIC EMBRYOS WOODY PLANT BIOTECH APS (DK) 2007-02-21 EP disclosed
WO-2007000056-A1 AROMATASE INHIBITORS FOR EMERGENCY CONTRACEPTION CASPER ROBERT F (CA) 2007-01-04 WO disclosed
EP-1661565-A1 COMPOSITION FOR THE TREATMENT OF VITILIGO Centro de Histoterapia Placentaria (CU) 2006-05-31 EP disclosed
US-6897065-B1 Method for maturation of conifer somatic embryos WOODY PLANT BIOTECH APS (DK) 2005-05-24 US disclosed
WO-2005011676-A1 COMPOSITION FOR THE TREATMENT OF VITILIGO CENTRO DE HISTOTERAPIA PLACENTARIA (CU) 2005-02-10 WO disclosed
EP-1217884-A1 METHOD FOR MATURATION OF CONIFER SOMATIC EMBRYOS Woody Plant Biotech APS (DK) 2002-07-03 EP disclosed
WO-2001020972-A1 METHOD FOR MATURATION OF CONIFER SOMATIC EMBRYOS WOODY PLANT BIOTECH APS (DK) 2001-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180235992-A1 IMMUNOTHERAPIES FOR MALIGNANT, NEURODEGENERATIVE AND DEMYELINATING DISEASES BY THE USE OF TARGETED NANOCARRIERS MAG, MSR1, CD47 APEX1 4240/4885GAA 610/4885ALDH1A1 3519/4885
US-20100105640-A1 Aromatase Inhibitors for Emergency Contraception CYP19A1, SHBG, HSD17B11 APEX1 299/4885GAA 2943/4885ALDH1A1 754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.